1 Growth Stock Down 40% to Buy Hand Over Fist Right Now

Medical device specialist DexCom (NASDAQ: DXCM) has encountered significant headwinds since last year. The company's financial results in 2024 weren't nearly as strong as the market had expected, and over the past eight months, it has faced the threat of tariffs that could harm its margins and bottom line. DexCom's shares are down by 40% since January 2024.Even so, the diabetes-focused company has several redeeming qualities that could enable it to deliver excellent returns over the next decade. Here's why DexCom stock is still a buy.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool